DOSING REGIMEN FOR TFPI ANTAGONISTS Russian patent published in 2022 - IPC A61K39/395 C07K16/40 A61P7/04 

FIELD: medicine.

SUBSTANCE: group of inventions relates to dosing regimens of TFPI antagonist antibodies for treating blood clotting disorders. The methods involve administering an antibody or an antigen-binding fragment thereof to an individual, wherein said antibody specifically binds to the epitope in the Kunitz domain 2 (K2) of the tissue factor pathway inhibitor (TFPI): a) with an initial dose of 300 mg and with one or more subsequent weekly doses of 150 mg; b) with a weekly dose of 300 mg, or c) with a weekly dose of 450 mg. The antibody or antigen-binding fragment thereof comprises a heavy chain with the amino acid sequence SEQ ID NO: 19 and a light chain with the amino acid sequence SEQ ID NO: 12.

EFFECT: methods contribute to shortening the time of bleeding in an individual, treating haemophilia A, B or C in an individual in need thereof, reducing the annual bleeding rate (ABR); after administration, ABR is reduced by at least 80% and amounts to no more than 1 to 4 bleedings per year.

32 cl, 3 dwg, 5 tbl, 2 ex